Coded Characteristics for Each Meta-Analysis

StudyESwNLength of Time on Medication, d Release TypeMean Total Dosage/d, mgFrequency Dosage/dFrequency Stimulants/wkNo. of Nights AssessedMethod of Sleep AssessmentStimulant Medication ClassPharmaceutical Company FundingProportion of Male Subjects in Sample, %Mean Age of Sample, mo
Sleep latency: baseline sleep versus medicated sleep
Chatoor et al80.768.0472.5LA30.03.02.51PSGAMPYes108.0
Corkum et al31.1518.81217.0SA22.53.07.028ActigraphyMPHNo71.0102.0
Galland et al320.8140.06272.02PSGMPHNo77.8126.0
Giblin and Strobel330.4425.451228.0LA48.7515PSGAMPYes41.7126.0
Sangal et al341.0851.745049.0SA3.07.028ActigraphyMPHYes75.3120.0
Schwartz et al150.4892.60447.0SA2.07.014ActigraphyMPHNo84.1110.4
Tirosh et al160.7911.86108.0MA15.61.257.012ActigraphyMPHNo72.7116.0
Sleep efficiency: baseline sleep versus medicated sleep
 Chatoor et al8−1.762.5372.5LA30.03.02.51PSGAMPYes108.0
 Corkum et al3−0.0755.16217.0SA22.53.07.028ActigraphyMPHNo71.0102.0
 Galland et al32−0.87836.83272.02PSGMPHNo77.8126.0
 Giblin and Strobel330.4821.581628.0LA48.715ActigraphyAMPYes41.7126.0
 Gruber et al35−0.4175.25345.0SA2.05.010ActigraphyMPHYes85.3110.4
 Schwartz et al15−0.4693.86447.0SA2.07.014ActigraphyMPHNo84.1110.4
 Tirosh et al16−0.4916.83108.0MA15.61.257.012ActigraphyMPHNo72.7116.0
 Corkum et al3−1.3115.73217.0SA22.503.07.028ActigraphyMPHNo71.0102.0
 Galland et al32−1.0729.01272.02PSGMPHNo77.8126.0
 Gruber et al35−0.1690.58345.0SA2.05.010ActigraphyMPHNo85.3110.4
 Sangal et al34−0.5697.065049.0SA3.07.028ActigraphyMPHYes75.3120.0
 Santisteban et al17−0.2991.583721.0LA20.01.07.028ActigraphyAMPYes73.0139.2
 Schwartz et al15−0.4792.93447.0SA2.07.014ActigraphyMPHNo84.1110.4
 Tirosh et al16−0.6913.53108.0MA15.61.257.012ActigraphyMPHNo72.7116.0
  • Negative effect size represents lower sleep efficiency and total sleep time values after being medicated with a stimulant; positive effect size represents greater sleep latency values after being medicated with a stimulant. The length of time on medication (days) was coded as number of days in the study that the child took stimulant medications. The release type was how long the stimulants are expected to last (short-acting [SA], medium-acting [MA], or long-acting [LA]). The mean total dosage per day (in milligrams) was coded as the average milligram of stimulants that children took in a day. The frequency dosage per day was coded as the number of times a child took stimulants in a day. The frequency stimulants per week were coded as number of days a week the child took medication. The number of nights assessed were coded as the number of nights a child wore an actigraph or participated in overnight PSG. Method of sleep assessment was coded as 1 = actigraphy, 2 = PSG. Stimulant medication class was coded as 1 = methylphenidate (MPH), 2 = amphetamine (AMP). Pharmaceutical company funding was coded as 0 = no, 1 = yes. Proportion of male subjects in the sample was coded as the number of male subjects divided by the number in total sample. The mean age of the sample was coded as mean age in months. ES = Hedges’ g; N, number of youth in the study; w, inverse of the variance. —, indicates that the information was not available for that study.